Drug
Flucytosine clinical trials
Also written Ro 2-9915 and 5-fluorocytosine.
Includes 9 studies of Extended Release Flucytosine.
- studies test it
- 25
- open now
- 2
- in phase 3
- 5
- first study started
- 2009
Keep track of what changes. Save the Flucytosine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Other names
Combined with it in one product
Studies by the year they started
23 studies that test it; most in 2020 (4)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 1 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 4 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 10
- Phase 3
- 5
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 11
Tocagen Inc. (7) · Transgene (3) · City of Hope Medical Center (2) · University of Minnesota (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Pfizer (1) · Duke University (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Vocimagene amiretrorepvec (7) · Fluconazole (5) · Amphotericin B (4) · Oncolytic Vaccinia Virus TG6002 (3) · Itraconazole (1) · Liposomal amphotericin B (1) · Temozolomide (1) · CD-expressing Bifidobacterium APS001F (1)
Studies
Open first, then newest update. How each study uses Flucytosine is read from its arms, and is right about nine times in ten.
Testing it · 25
- Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)Not yet recruitingPhase 3Duke UniversityNCT06525389Written as Flucytosine (5FC)
- DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade GliomaRecruitingPhase 1/2University of California, San FranciscoNCT06504381Written as DB107-FC
- Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed GlioblastomaWithdrawnPhase 2/3NRG OncologyNCT04105374Written as Extended Release Flucytosine
- Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal MeningitisCompletedPhase 2University of MinnesotaNCT06414512Written as Flucytosine
- Study of Intrahepatic Arterial Infusion of TG6002 in Combination With 5-FC in Patients With Metastatic Colorectal CancerTerminatedPhase 1/2TransgeneNCT04194034Written as Flucytosine (5-FC)
- Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.TerminatedPhase 1/2TransgeneNCT03724071Written as Flucytosine (5-FC, Ancotil)
- Clinical Study of ABCD in the Treatment of Cryptococcal MeningitisStatus unknownNot applicablePeking Union Medical College HospitalNCT05471063Written as flucytosine
- A Randomized Double Blind Protocol Comparing Amphotericin B With Flucytosine to Amphotericin B Alone Followed by a Comparison of Fluconazole and Itraconazole in the Treatment of Acute Cryptococcal MeningitisCompletedNot applicableNational Institute of Allergy and Infectious Diseases (NIAID)NCT00000639Written as Flucytosine
- Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade GliomasCompletedPhase 1City of Hope Medical CenterNCT02015819Written as flucytosine
- Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal InfectionTerminatedPhase 2Yale UniversityNCT01562132Written as Flucytosine and fluconazole
- Phase I/II Study of APS001F With Flucytosine and Maltose in Solid TumorsSuspendedPhase 1/2Anaeropharma Science, Inc.NCT01562626Written as Flucytosine (5-FC)
- Safety, Tolerability and Pharmacokinetics Characteristics of Recombinant Oncolytic Vaccinia Virus Injection T601 as a Single Drug or in Combination With Oral Flucytosine (5-FC), in Patients With Advanced Malignant Solid TumorsStatus unknownPhase 1/2Tasly Tianjin Biopharmaceutical Co., Ltd.NCT04226066Written as T601+5-FC
- A Safety Study of TMV-018 in Patients With Tumors of the Gastrointestinal TractWithdrawnPhase 1Themis Bioscience GmbHNCT04195373Written as TMV-018 + 5-FC
- A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511TerminatedPhase 1Tocagen Inc.NCT04327011Written as Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
- A Study of Toca 511 & Toca FC in Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer (Toca 8)WithdrawnPhase 1Tocagen Inc.NCT04089163Written as Toca FC (extended-release formulation of flucytosine)
- A Study of the Safety of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Subjects With Newly Diagnosed High Grade Glioma Receiving Standard of CareWithdrawnPhase 1Tocagen Inc.NCT02598011Written as Toca FC
- A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)TerminatedPhase 1Tocagen Inc.NCT02576665Written as Toca FC
- The Toca 5 Trial: Toca 511 & Toca FC Versus Standard of Care in Patients With Recurrent High Grade GliomaTerminatedPhase 2/3Tocagen Inc.NCT02414165Written as Toca FC
- AmB Dose for Cryptococcal MeningitisStatus unknownPhase 3Shanghai Public Health Clinical CenterNCT04140461Written as Flucytosine
- Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain TumorCompletedPhase 1Tocagen Inc.NCT01470794Written as Toca FC
See all 25 studies that test Flucytosine →
Given in every arm · 3 — Flucytosine is usual care beside what is tested
- DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic AstrocytomaRecruitingPhase 2Ashish ShahNCT06264388Written as DB107-FC
- Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant GliomaCompletedPhase 1/2Beijing Neurosurgical InstituteNCT06562621Written as ONF
- A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant GliomaCompletedPhase 1Tocagen Inc.NCT01156584Written as Toca FC
Codes
What other systems call Flucytosine · ClinicalTrials.gg INT007500
- MeSH (NLM) D005437FlucytosineConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) D83282DT06FLUCYTOSINEConfirmed FDA, NLM
- RxNorm 4451One source FDA
- NCI Thesaurus C501FlucytosineOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005437 | Flucytosine | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | D83282DT06 | FLUCYTOSINE | Confirmed FDA, NLM |
| RxNorm | 4451 | — | One source FDA |
| NCI Thesaurus | C501 | Flucytosine | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.